Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029314 | 0.89 | BDKRB1 (0.88) | BDKRB1 | |
| SCHEMBL4027533 | 0.87 | BDKRB1 (0.78) | BDKRB1NISCH | |
| SCHEMBL4028407 | 0.85 | BDKRB1 (0.54) | BDKRB1NISCH | |
| SCHEMBL4035729 | 0.84 | BDKRB1 (0.79) | BDKRB1 | |
| SCHEMBL4027059 | 0.83 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4033685 | 0.82 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL5118103 | 0.82 | BDKRB1 (0.50) | BDKRB1 | |
| SCHEMBL4033419 | 0.81 | BDKRB1 (0.84) | BDKRB1 | |
| SCHEMBL4033399 | 0.80 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4028386 | 0.80 | BDKRB1 (0.72) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | claimed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | claimed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | claimed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | claimed |
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | disclosed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | BDKRB1 11/4885NISCH 3284/4885 |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885NISCH 2280/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | BDKRB1 12/4885NISCH 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.